Research progress of decitabine in treatment of hematologic diseases

国际输血及血液学杂志 Pub Date : 2019-01-20 DOI:10.3760/CMA.J.ISSN.1673-419X.2019.01.012

Lang Peng

引用次数: 0

Abstract

Studies show that DNA methylation play an important role during the transformation of hematopoitic diseases. Decitabine is a kind of demethylation drug that can inhibit DNA methyltransferase. Currently, decitabine is mainly used to treat hematological diseases, such as myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), etc., due to its unique mechanisms and better clinical effectiveness. In recent years, decitabine is also used for steroid-resistant/refractory primary immune thrombocytopenia (ITP) patients, which can improve platelet count, reduce bleeding risk and improve patients′ prognosis. In order to explore the clinical application of decitabine, this article summarizes the research progress on decitabine for treatment of hematopoietic disease. Key words: Myelodysplastic syndromes; Hematologic diseases; Leukemia, myeloid; Purpura, thrombocytopenic, idiopathic; Decitabine

查看原文本刊更多论文

地西他滨治疗血液病的研究进展

研究表明，DNA甲基化在造血疾病的转化过程中起着重要作用。地西他滨是一种抑制DNA甲基转移酶的去甲基化药物。目前，地西他滨主要用于治疗血液系统疾病，如骨髓增生异常综合征(MDS)、急性髓系白血病(AML)、慢性髓单细胞白血病(CMML)等，因其作用机制独特，临床疗效较好。近年来，地西他滨也被用于类固醇耐药/难治性原发性免疫性血小板减少症(ITP)患者，可提高血小板计数，降低出血风险，改善患者预后。为了探索地西他滨的临床应用，本文综述了地西他滨治疗造血疾病的研究进展。关键词:骨髓增生异常综合征;血液疾病;白血病,骨髓;紫癜，血小板减少，特发性;Decitabine

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

国际输血及血液学杂志

自引率

0.00%

发文量

10610

期刊介绍： The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.